Search | Médecins Sans Frontières Access Campaign

277 results found

Technical brief |

15 November 2023

Access to TB Testing and Treatments: GeneXpert and Delamanid

The access barriers on lifesaving TB tools

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert CepheidOtsuka

Dr Samsuddin Khan performs physical exam of Deepak Sabhash Shegar, a person living with DR-TB, at MSF DR-TB clinic, Chembur, Mumbai, India, 2022

Press release |

15 November 2023

Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

endTB clinical trial offers new shortened drug regimens to treat multidrug-resistant TB

Tags Tuberculosis drug-resistant TBtuberculosis UNITAID

MSF Medical Doctor Ramya, conducting physical examination of female DRTB patient during her follow-up visit to endTB clinic.

Press release |

14 November 2023

MSF warns governments are failing to test, treat and prevent TB in children

Governments must immediately implement latest WHO guidelines to stop children dying from TB

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert World Health Organization

GeneXpert test technology has revolutionised the diagnosis of TB, allowing detection of the TB bacterium, and its resistance to drugs, in only two hours.

Press release |

07 November 2023

MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease

Recent price reductions to WHO-recommended TB tests and treatment should enable more countries to make these vital medical tools available

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpertbedaquiline World Health Organization

Vaishnavi, 7, who lives with drug-resistant TB, interacts with MSF nurse Prachi, as her mother Vishaka holds her. Mumbai, India, 2022.

Press release |

22 September 2023

Commitments made in today's UN TB Declaration to scale up TB testing and treatment, and improve TB care for children, require immediate, concrete action

Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB

Tags Tuberculosis drug-resistant TBtuberculosis

Fact sheet |

22 September 2023

Tuberculosis: Challenges and Breakthroughs

Despite being curable, why is TB the world’s deadliest infectious disease? What tools do we have to beat the disease?

Tags Tuberculosis drug-resistant TBtuberculosis

GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Press release |

19 September 2023

TB test price reduction by Cepheid and Danaher is an important step in the right direction

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert Johnson & Johnson

Bottle of bedaquiline, Zhytomyr Regional TB Dispensary, Ukraine. In 2018, MSF started providing treatment for drug-resistant TB to people in Zhytomyr, Ukraine.

Photo credit: Oksana Parafeniuk

Blog |

15 September 2023

The long and winding road to ensure affordable access to a key TB drug

With the United Nations High-Level meeting just over the horizon, the TB community is ready to amplify the voices of people affected by TB around the world at this global forum, and demand the global attention and resources needed to beat this devastating yet curable disease.

Letter |

31 July 2023

Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply

Open letter by CSOs to US pharma J&J seeking clarification on the deal for supply of generic versions of TB bedaquiline

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline Johnson & Johnson

Press release |

26 April 2023

MSF demands J&J give up its patent monopoly on TB drug to put lives over profits

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline Johnson & Johnson

Bibi Amina and her granddaughter Sayeeda wait to see a doctor at MSF's DR-TB hospital in Kandahar, Afghanistan, September 2022

Press release |

22 March 2023

Urgent need to improve access to TB testing to support rollout of better, safer, shorter treatment for drug-resistant TB

MSF called on governments and donors to speed up access to diagnostic tests, and shorter, safer and more effective treatments, for DR-TB.

Tags Tuberculosis drug-resistant TB GeneXpert World Health Organization

Dr Zulfiya Dustmatova works as a medical doctor with MSF in Tajikistan, where our teams work with the Ministry of Health and Social Protection to diagnose and treat children with drug-resistant TB (DR-TB).

Blog |

01 March 2023

One step at a time: Improving treatment options for children with drug-resistant TB in Tajikistan

Dr Zulfiya Dustmatova works as a medical doctor with MSF in Tajikistan, where our teams work with the Ministry of Health and Social Protection to diagnose and treat children with drug-resistant TB (DR-TB).

Medical cooler box for the transportation of specimens (blood/sputum) from the point of specimen collection to the laboratory, used for the TB-PRACTECAL clinical trial. Clinical laboratory specimens must be transported at proper temperatures in order to preserve the viability and integrity of the specimen.

Press release |

22 December 2022

TB-PRACTECAL: Groundbreaking MSF trial finds better treatment for people with drug-resistant tuberculosis

Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of ...

Tags Tuberculosis drug-resistant TB TB AllianceJohnson & Johnson DRTB Drugs Under the Microscope

Dr Abdu Samya Bashagha checking X-ray scan of a patient in Abu Sitta Hospital where MSF is running TB support activities

Research article |

19 April 2022

BMJ Global Health: Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study

MSF authors analyse R&D and regulatory approval of DR-TB drugs bedaquiline and delamanid, and impact on treatment outcomes and access.

Tags Tuberculosis drug-resistant TB bedaquilinedelamanid research and development (R&D)

MSF Nurse taking vitals of nine years old XDRTB + EPTB male child at MSF independent Clinic, Mumbai- India

Press release |

20 April 2021

MSF supports TB survivors’ court case for Indian government to override patents on lifesaving TB drugs

Next week the Indian government is expected to decide whether it is willing to override patents on two critical tuberculosis (TB) drugs following a court petition filed at the Mumbai High Court by two survivors of TB and activists. MSF ...

Tags Tuberculosis drug-resistant TB bedaquilinedelamanid Johnson & JohnsonOtsuka

Kam Thianlam (42) is an MDR-TB patient at MSF’s clinic in Churachandpur. He lives in Laisang, a remote place. Irene, MSF "Direct Observation Treatment Procedures" nurse, teaches MSF nurse teaches Akungmei, a newly recruited DOTs nurse how to administer the 15 tablets he needs to take everyday so that she can follow up his adherence.

Press release |

16 November 2020

Report shows new tests and drugs for world’s deadliest infectious disease, TB, remain out of reach

MSF calls on governments and donors to step up and speed up TB testing and treatment

Tags Tuberculosis drug-resistant TBtuberculosis World Health Organization

Issue brief |

19 October 2020

DR-TB and TB-Prevention Drugs Under the Microscope, 7th Edition

Medicine pricing and patent issues for drug-resistant tuberculosis and tuberculosis prevention

Tags Tuberculosis drug-resistant TBtuberculosis pretomanidbedaquilinedelamanid Union Conference on Lung HealthJohnson & JohnsonOtsuka DRTB Drugs Under the Microscope

Nobuhle Titus, an MSF nurse technical support, packs sputum samples collected from a Luyanda site in the town of Vuma. Luyanda sites She collects and transports the samples from MSF’s Luyanda sites to the hospital where they are tested. Luyanda sites provide a link between patients and hospitals where patients can have sputum samples tested and receive information on TB and other diseases. This process makes the process of testing TB easier for patients who often stay far away from the hospital.

Press release |

14 October 2020

MSF response to the release of WHO Global TB Report 2020

The World Health Organization (WHO) released today the 2020 edition of its Global Tuberculosis (TB) Report. The report, which WHO releases annually, features data on disease trends and the response to the epidemic in 198 countries and ...

Tags Tuberculosis drug-resistant TBtuberculosis World Health Organization

Report

Step Up for TB: TB policies in 37 countries, 4th Ed.

Tuberculosis is the world’s deadliest infectious disease and kills 1.4 million people a year. The latest diagnostic tests can rapidly and accurately diagnose TB. New medicines can help prevent and cure TB. Yet two years after a United ...

Tags Tuberculosis drug-resistant TBtuberculosis [TB] Out of Step

Statement |

04 February 2020

WHO 146th EB - 10 (EB146/11) – Ending tuberculosis

MSF Statement: Agenda item 10 (EB146/11) – Ending tuberculosis

Tags Research and development drug-resistant TBtuberculosis WHO Executive Board

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Access to TB Testing and Treatments: GeneXpert and Delamanid

Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

MSF warns governments are failing to test, treat and prevent TB in children

MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease

Commitments made in today's UN TB Declaration to scale up TB testing and treatment, and improve TB care for children, require immediate, concrete action

Tuberculosis: Challenges and Breakthroughs

TB test price reduction by Cepheid and Danaher is an important step in the right direction

The long and winding road to ensure affordable access to a key TB drug

Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply

MSF demands J&J give up its patent monopoly on TB drug to put lives over profits

Urgent need to improve access to TB testing to support rollout of better, safer, shorter treatment for drug-resistant TB

One step at a time: Improving treatment options for children with drug-resistant TB in Tajikistan

TB-PRACTECAL: Groundbreaking MSF trial finds better treatment for people with drug-resistant tuberculosis

BMJ Global Health: Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study

MSF supports TB survivors’ court case for Indian government to override patents on lifesaving TB drugs

Report shows new tests and drugs for world’s deadliest infectious disease, TB, remain out of reach

DR-TB and TB-Prevention Drugs Under the Microscope, 7th Edition

MSF response to the release of WHO Global TB Report 2020

Step Up for TB: TB policies in 37 countries, 4th Ed.

WHO 146th EB - 10 (EB146/11) – Ending tuberculosis